Day: February 22, 2026

CALGARY, Alberta, Feb. 22, 2026 (GLOBE NEWSWIRE) — (“Canacol” or the “Company”) announces a leadership change and the appointment of an independent director to the board of directors (the “Board”). The Board believes that these changes will position the Company for success in the next phase of its restructuring by adding substantial restructuring experience to the Board. Mr. Jason Bednar, Canacol’s Chief Financial Officer, and Mr. Ravi Sharma, Canacol’s Chief Operating Officer, will assume roles as Interim Co-Chief Executive Officers of the Company effective immediately. Mr. Bednar will continue in his role as Chief Financial Officer and Mr. Sharma will continue in his role as Chief Operating Officer while also assuming the responsibilities as Interim Co-Chief Executive Officers. In this role, they will jointly oversee the Company’s...

LONDON, Feb. 22, 2026 (GLOBE NEWSWIRE) — nVent Electric plc (NYSE: NVT) (“nVent”), a global leader in electrical connection and protection solutions, today announced that it is postponing its Investor Day, originally scheduled for February 24, 2026, due to a state of emergency declared for the New York metropolitan area ahead of a major winter storm, expected to bring blizzard conditions. nVent is currently evaluating scheduling options. A formal invitation will be issued once the new date and location are finalized. This postponement is strictly due to weather-related logistics and is not related to any change in the company’s operations, financial performance or outlook. About nVentnVent is a leading global provider of electrical connection and protection solutions. We believe our inventive electrical solutions enable safer systems...

In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12 Consistently, other clinical and imaging scores also showed improvements of 80+% by week 12 for patients treated with SLK, including ASDAS-CRP and SPARCC MRI axSpA is a disease driven by inflammation leading to irreversible ossification (via osteoblast activity) and ultimately to irreversible restriction of mobility – objective PET/MRI imaging data further showed a significant reduction in inflammation and osteoblast activity deep in affected joints, already by week 12, suggesting potential for disease modification in axSpA for SLK As a biomarker-controlled trial, S-OLARIS data showed SLK reduced the levels of key inflammatory mediators in axSpA, in peripheral...